SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff has centered on concerns about its debt burden, distressed bond trading, and ability to finance its AI data-center expansion. Goldman Sachs Buy upgrade prompted hopes for a rebound, but traders debated whether the move could overcome financing risks, with bearish concerns about dilution or default competing with dip-buying and oversold-bounce calls.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention for its steep slide to fresh lows, as traders question the companys business prospects and debate whether Trumps political standing and the approaching midterms could further weaken its appeal. Sentiment is heavily bearish, though a few traders see the decline as a buying opportunity or cite possible merger and fusion developments.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs continued slide to fresh lows is being tied to soft residential roofing demand, housing-sector pressure and analyst target cuts, with traders also pointing to high rates and suspected dilution. Many are frustrated by the decline and managements limited communication, while some long-term holders remain optimistic about the building-products roll-up and future integration gains.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

CBRS is drawing attention amid a steep post-IPO selloff, with traders pointing to IPO lockup share releases and reported insider selling as potential sources of pressure, alongside concerns about valuation, growth, and reliance on OpenAI. Bears expect further downside, while some bulls view the decline as overdone and are averaging in.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is drawing attention for its steep selloff and persistent underperformance, with traders citing weakness in crypto and AI infrastructure alongside concern about its CoreWeave tenancy and delays in securing additional data-center tenants. Many blame management and a lack of communication, while some remain hopeful that Helios revenue or earnings will demonstrate the businesss potential.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood shares are under pressure amid a sustained selloff, with analyst caution and valuation concerns ahead of earnings adding to traders worries; some also point to broader market weakness and crypto declines. The bearish mood and speculation about insider selling or unusual activity contrast with dip-buyers who see the decline as an opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDAs acceptance of CorMedixs REZZAYO supplemental application for priority review in invasive fungal-disease prevention is drawing attention, with traders focused on the potential label expansion and upcoming regulatory decision. Enthusiasm is tempered by frustration that the news has barely moved the share price and broader concerns about DefenCaths reimbursement and competition; acceptance does not guarantee approval.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after its Phase 3 APOLLO trial of bitopertin met both primary and all secondary endpoints in erythropoietic protoporphyria, strengthening the case for an FDA resubmission after an earlier rejection. Traders are weighing the positive results and potential short-covering against profit-taking, heavy selling, and the remaining regulatory uncertainty.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoin and broader crypto-market volatility are driving attention, with traders repeatedly criticizing COIN for falling sharply on weak crypto days while lagging during rebounds. Sentiment is split between frustration over its underperformance and hopes for a recovery, with upcoming quarterly results adding to the debate.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs better-than-guided third-quarter results and upbeat outlook for higher EBITDA have driven a sharp rally, with traders also discussing potential short covering. Bulls see improving steel pricing and contracts supporting a recovery, while skeptics question whether the outlook can overcome the companys debt and past volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBios FDA expansion of ANKTIVA for papillary-only BCG-unresponsive bladder cancer, alongside updated long-term trial data, is driving attention. Traders are debating the sharp selloff despite the positive developments, variously attributing it to sell-the-news trading, options activity and broader biotech weakness, while others allege short manipulation; revenue growth and commercial uptake remain key concerns.

The pullback appears tied to profit-taking after the FDA expanded ANKTIVAs bladder-cancer label to include papillary-only disease, with traders describing a sell-the-news reaction after a sharp run-up. Some are also focused on whether the expanded indication will translate into revenue growth, with upcoming earnings seen as an important test.

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus...

FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer

IBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.

ImmunityBio Stock Climbs Thursday: What's Going On?

ImmunityBio shares are trading higher Thursday after the FDA approved expansion for its bladder cancer therapy ANKTIVA.read more...

Why Are Nasdaq Futures Sinking Premarket? CRWV, MU, TSM, SKHY, IBRX, RKLB, TSLA Stocks In Focus

Equity

On Stocktwits, retail sentiment toward SPY has moderated to ‘neutral,’ but remained ‘bullish’ on QQQ despite the global tech rout. 


Dow, S&P 500, Nasdaq Decline Amid Hot Inflation Data, AI Selloff: CRWV, NBIS, NVDA, IBRX Stocks In Focus

Red-hot inflation data, triggered by soaring energy prices, weighed heavily on markets on Wednesday.

IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk 

Founder Patrick Soon-Shiong has signaled a trial-status discussion at Friday’s Piper Sandler fireside chat.

FDA Expands ANKTIVA Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Gurin (BCG) to include patients...

Why Is ImmunityBio Stock Gaining Wednesday?

ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.read more...

IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline

FDA approved the drug Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer that has not responded to a specific therapy called Bacillus Calmette-Guérin and has not invaded the bladder muscle.


SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals

J&J is open to strategic acquisitions and targets more than $50 billion in oncology sales by 2030.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Global semiconductor stock selloff has hit risk appetite. South Korea’s Kospi slipped over 7% on Thursday, with SK Hynix and Samsung among the hardest-hit stocks.</li><li>TSM, the world’s largest contract chipmaker, reported strong Q3 earnings and raised its 2026 guidance.</li><li>Investors will be watching for the release of September Producer Price Index (PPI), retail sales and weekly jobless claims data. Fed Chair Kevin Warsh is scheduled to speak at the IMF meeting later today.</li></ul>U.S. stock futures were mixed early on Thursday as a broad selloff in global tech stocks and a hotter-than-expected CPI inflation print weighed on investor sentiment. Concerns over artificial intelligence (AI) infrastructure spending, combined with rising bond yields and Fed rate hike fears, have kept the market cautious.Asian markets took a knock, with South Korea’s KOSPI plunging over 7% and triggering a trading halt, led by a crack in heavyweights Samsung and SK Hynix.&nbsp;As of 4 a.m. ET, Nasdaq futures fell 1%, S&amp;P 500 futures were down 0.3%, while Dow and Russell 2000 futures gained 0.4%.On Stocktwits, retail sentiment for the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>,&nbsp;which tracks the S&amp;P 500 Index, has moderated to ‘neutral’ from ‘bullish’ a day ago, while&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a>, which tracks the Nasdaq-100 Index, has remained&nbsp;‘bullish’ despite the selloff in semiconductor stocks.&nbsp;<h2 class="st-heading-2">Rate Hike Fears Re-Emerge</h2>On Wednesday, the inflation print showed September CPI rising 0.6% month-on-month and 3.7% year-on-year, coming in above street estimates. With 10-year Treasury yields hovering around 5%, CME Fedwatch now puts expectations for a Fed rate hike at the upcoming October meeting at 27%.&nbsp;Investors will be watching for the release of September Producer Price Index (PPI), retail sales, and weekly jobless claims data today. More importantly, Fed Chair Kevin Warsh is scheduled to speak at the IMF meeting later today. His commentary could offer clues on how policymakers are assessing the current macroeconomic situation.&nbsp;Noted investor Michael Burry has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-warns-wall-street-pain-trade-mag-7-red-october-call/cZxWFGQRBAf">warned</a> of long-lasting market pain, as falling Treasury yields do not guarantee an equity rally. He added that semiconductors have already seen a selloff along with yields, and now a similar move across the Mag 7 stocks could add conviction to his ‘Red October’ call.&nbsp;<h2 class="st-heading-2">The Tech Radar</h2>A new Gartner report has raised warnings, saying that over $3.5 trillion in AI infra spending faces write-down risks by 2030, and that over 80% of neocloud providers could lose their independent operations. This sparked a rout across AI cloud stocks on Wednesday.&nbsp;CoreWeave (CRWV) and Nebius (NBIS) continue to see sharp dips along with other neocloud peers, even as CoreWeave CEO reaffirmed confidence in the company’s $99B backlog. Additionally, Cathie Wood’s ARK Investment bought 189K shares on Wednesday. And Dan Ives stated that the fears around Coreweave’s selloff were “way overdone.”&nbsp; Taiwan Semiconductor Manufacturing Co (TSM): Shares fell over 2% in early premarket trade despite&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsm-stock-still-caught-in-ai-chip-rout-despite-record-q3-profit-and-bright-outlook-retail-stays-bullish/cZxWnqCRBAO">raising</a> its 2026 revenue guidance and posting a record Q3 profit.&nbsp;Micron Technology (MU): Shares reel under pressure in early premarket trading amid global memory weakness. Separately, reports suggest the Taiwan President has urged management and unions to resolve bonus disputes to avoid a strike at Micron’s Taiwan HBM packaging hub.&nbsp;SK Hynix (SKHY): Shares have slipped for the eighth session amid reports that the company is seeking U.S. approval to export American chipmaking equipment to Chinese facilities as a precondition for building a factory in the U.S.Nvidia (NVDA), Broadcom (AVGO), and Qualcomm (QCOM) are also in the red, tracking broad-based weakness across the sector and amid reports that ByteDance is in advanced talks with MediaTek about custom AI data center chips.The iShares Semiconductor ETF (SOXX) and the VanEck Semiconductor ETF (SMH) fell over 2%.<h2 class="st-heading-2">Trending Stocks</h2>Tesla (TSLA): Shares fell nearly 2% in early premarket trade ahead of its Roadster event, which CEO Elon Musk has promised will be the ‘greatest product demo of all time’. Retail is also tracking a Barclays note that suggested a potential Tesla-SpaceX merger announcement is likely before Tesla’s annual meeting that takes place in early December.&nbsp;SpaceX (SPCX): Elon Musk claims that the company’s valuation could top $100 trillion within 10 years.&nbsp;AST SpaceMobile (ASTS): Shares fell 4% in early premarket trade, tracking broader sector weakness. Meanwhile, analysts have highlighted timeline risks suggesting that the company’s 60-satellite milestone could slip to 2028.&nbsp;Rocket Labs (RKLB) shares fell 10% in early premarket trade, and retail sentiment on Stocktwits fell to an all-time low after the company announced a delay of its reusable Neutron rocket launch to 2027.&nbsp;ImmunityBio (IBRX) shares rose 2% in early premarket trade after the FDA expanded approval of its immunotherapy drug, Anktiva, for papillary non-muscle invasive bladder cancer. Jefferies raised the firm’s price target to $14 from $12 and maintained a Buy call, noting that the approval came about three months ahead of the January 2027 PDUFA deadline.Vanda Pharmaceuticals (VNDA) shares fell 5% in early premarket trade after announcing that its phase 3 trial of VQW-765 for acute social anxiety failed to meet its primary endpoint, putting the clinical program on hold.&nbsp;Skydance (SKYD) remains on the retail radar after clarifying an NYSE reference price adjustment to its Class B warrants, reducing the overall common valuation to $45.6 billion.Netflix (NFLX) shares held steady in early premarket, even as retail sentiment on Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nflx-stock-dips-overnight-retail-turns-bearish-ahead-of-earnings-as-netflix-reels-under-growth-pressure/cZxWltGRBAc">dipped</a> into ‘bearish’ territory ahead of its earnings report next week.&nbsp;Other tickers trending on Stocktwits at the time of writing included Iren Limited (IREN), Lockheed Martin (LMT), and Shopify (SHOP).<h2 class="st-heading-2">What Else To Watch On Thursday</h2>On the earnings front, Charles Schwab Corp. (SCHW), U.S. Bancorp. (USB), PNC Financial Services Group Inc. (PNC), Prologis Inc. (PLD), Bank of New York Mellon Corp. (BNY), Alcoa Corp. (AA), and NextTrip Inc. (NTRP) are among those reporting today.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]comOn the earnings front, Charles Schwab Corp. (SCHW), U.S. Bancorp. (USB), PNC Financial Services Group Inc. (PNC), Prologis Inc. (PLD), Bank of New York Mellon Corp. (BNY), Alcoa Corp. (AA), and NextTrip Inc. (NTRP) are among those reporting today.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

A laptop keyboard, a reflected illustrative stock graph displayed on a screen and the Nasdaq logo. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

U.S. stock futures were mixed early on Thursday as a broad selloff in global tech stocks and a hotter-than-expected CPI inflation print weighed on investor sentiment. Concerns over artificial intelligence (AI) infrastructure spending, combined with rising

Micron Technology Inc

Rocket Lab USA Inc

Taiwan Semiconductor Manufacturing - ADR

$SLS

$ONDS

$IBRX

$PYPL

Which of these trending stocks are you most bullish on right now - $SLS, $ONDS, $IBRX, or $PYPL?

Stocktwits

SELLAS Life Sciences Group Inc

Ondas Inc

PayPal Holdings Inc

Which of these trending stocks are you most bullish on right now - 

Stocktwits Polls

Retail investors are actively rallying to hold positions, aiming to trap shorts and trigger a potential gamma squeeze after price volatility.

Investors express frustration over perceived stock price manipulation, blaming coordinated efforts by hedge funds and 'cockroaches' to suppress value.

The recent FDA label expansion for NMIBC papillary treatment is seen as a key growth catalyst despite recent sell-offs.

Long-term believers are taking advantage of recent price drops to load the boat, viewing the current market dip as a massive buying opportunity.

Current Price	$8.62
Prev Close	$9.18
Open	$9.21
Dividend Yield	0.00%
50-Day Moving Average	$8.56
Beta	1.82
Avg. Volume	11.19M
PE Ratio	-9.47

52-Week High	$12.43
52-Week Low	$1.95
Market Capitalization	$9.73B
EPS (Annual)	-$0.382
Price to Book	-9.24
Revenue Per Employee	$163,947.90

Feed

News

Sentiment

Earnings

Fundamentals

Info

IBRX Fundamentals